Literature DB >> 22723755

How to read a clinical trial paper: a lesson in basic trial statistics.

Shail M Govani1, Peter D R Higgins.   

Abstract

While the number of clinical trials performed yearly is increasing, the application of these results to individual patients is quite difficult. This article reviews key portions of the process of applying research results to clinical practice. The first step involves defining the study population and determining whether these patients are similar to the patients seen in clinical practice in terms of demographics, disease type, and disease severity. The dropout rate should be compared between the different study arms. Design aspects, including randomization and blinding, should be checked for signs of bias. When comparing studies, clinicians should be aware that the outcomes being studied may vary greatly from one study to another, and some outcomes are much more reliable and valuable than others. The definition of clinical response should also be scrutinized, as it may be too lenient. Surrogate outcomes should be viewed cautiously, and their use should be well justified. Clinicians should also note that statistical significance, as defined by a P-value cutoff, may be the result of a large sample size rather than a clinically significant difference. The treatment effect can be estimated by calculating the number needed to treat, which will demonstrate whether changes in clinical practice are worthwhile. Finally, this article discusses some common issues that can arise with figures.

Entities:  

Keywords:  Statistics; clinical research; clinical trials; outcomes; randomized controlled trials

Year:  2012        PMID: 22723755      PMCID: PMC3380258     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  25 in total

Review 1.  What is meant by intention to treat analysis? Survey of published randomised controlled trials.

Authors:  S Hollis; F Campbell
Journal:  BMJ       Date:  1999-09-11

2.  Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group.

Authors:  H C Bucher; G H Guyatt; D J Cook; A Holbrook; F A McAlister
Journal:  JAMA       Date:  1999-08-25       Impact factor: 56.272

3.  Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants.

Authors:  Linda S Elting; Catherine Cooksley; B Nebiyou Bekele; Michael Frumovitz; Elenir B C Avritscher; Charlotte Sun; Diane C Bodurka
Journal:  Cancer       Date:  2006-06-01       Impact factor: 6.860

Review 4.  Reporting of outcomes in orthopaedic randomized trials: does blinding of outcome assessors matter?

Authors:  Rudolf W Poolman; Peter A A Struijs; Rover Krips; Inger N Sierevelt; René K Marti; Forough Farrokhyar; Mohit Bhandari
Journal:  J Bone Joint Surg Am       Date:  2007-03       Impact factor: 5.284

5.  Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis.

Authors:  J Eaden; K Abrams; H McKay; H Denley; J Mayberry
Journal:  J Pathol       Date:  2001-06       Impact factor: 7.996

6.  Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine.

Authors:  G D'Haens; K Geboes; P Rutgeerts
Journal:  Gastrointest Endosc       Date:  1999-11       Impact factor: 9.427

7.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

8.  Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

Authors:  R Löfberg; P Rutgeerts; H Malchow; C Lamers; A Danielsson; G Olaison; D Jewell; O Ostergaard Thomsen; H Lorenz-Meyer; H Goebell; H Hodgson; T Persson; C Seidegård
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 9.  Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis.

Authors:  Sujal C Rangwalla; Akbar K Waljee; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2009-03       Impact factor: 5.325

10.  Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation.

Authors:  G Olaison; R Sjödahl; C Tagesson
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

View more
  2 in total

1.  Treatment of carotid stenosis in asymptomatic, nonoctogenarian, standard risk patients with stenting versus endarterectomy trials.

Authors:  Jon S Matsumura; Bret M Hanlon; Kenneth Rosenfield; Jenifer H Voeks; George Howard; Gary S Roubin; Thomas G Brott
Journal:  J Vasc Surg       Date:  2021-10-22       Impact factor: 4.860

2.  Efficacy of motivating short interventions for smokers in primary care (COSMOS trial): study protocol for a cluster-RCT.

Authors:  Thomas Grischott; Oliver Senn; Thomas Rosemann; Anja Frei; Jacques Cornuz; Eva Martin-Diener; Stefan Neuner-Jehle
Journal:  Trials       Date:  2019-01-25       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.